glembatumumab vedotin
mAbexperimentalADC
Glembatumumab vedotin is an antibody-drug conjugate (ADC) that targets cancer cells expressing transmembrane glycoprotein NMB (GPNMB). — Wikipedia
Clinical trial activity
11 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
9
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2006 (NCT00412828)
Timeline
Indications
Mechanism of action
- Transmembrane glycoprotein NMBBINDING AGENT
GPNMB binding agent
- Transmembrane glycoprotein NMBINHIBITOR
GPNMB inhibitor
- TubulinINHIBITOR
Tubulin inhibitor
Beta tubulin vinca binding domain
- Tubulin beta-4B chain (TUBB4B) ↗
- Tubulin beta-1 chain (TUBB1) ↗
- Tubulin alpha-3C chain (TUBA3C) ↗
- Tubulin alpha-4A chain (TUBA4A) ↗
- Tubulin beta-3 chain (TUBB3) ↗
- Tubulin alpha-1A chain (TUBA1A) ↗
- Tubulin beta-4A chain (TUBB4A) ↗
- Tubulin beta-8 chain (TUBB8) ↗
- Tubulin beta chain (TUBB) ↗
- Tubulin alpha-1B chain (TUBA1B) ↗
- Tubulin alpha-1C chain (TUBA1C) ↗
- Tubulin alpha-3E chain (TUBA3E) ↗
- Tubulin beta-2A chain (TUBB2A) ↗
- Tubulin beta-2B chain (TUBB2B) ↗
- Tubulin beta-6 chain (TUBB6) ↗
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
- Payload
- Monomethylauristatin E
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaGlembatumumab vedotin ↗
- ChEMBLCHEMBL2108707 ↗
- ChEMBLCHEMBL1743028 ↗
Also known as
- cdx-011
- cdx-011
- cdx-011
- cr011
- cr-011-vcmmae
- cr011-vcmmae
- glembatumumab
- glembatumumab vedotin
- glembatumumab vedotin
- glembatumumab vedotin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03473691 | Early Phase 1 (Phase 1) | May 1, 2018 | Celldex Therapeutics, University of Virginia |
| NCT03326258 | Phase 1/Phase 2 (Phase 2) | Apr 20, 2018 | Duke University, National Cancer Institute (NCI) |
| NCT03067935 | N/A | Feb 23, 2017 | Celldex Therapeutics |
| NCT02713828 | Phase 1/Phase 2 (Phase 2) | Apr 10, 2016 | Celldex Therapeutics, PrECOG, LLC. |
| NCT02487979 | Phase 2 | Feb 16, 2016 | National Cancer Institute (NCI) |
| NCT02363283 | Phase 2 | Sep 16, 2015 | National Cancer Institute (NCI), University of Texas at Houston |
| NCT02302339 | Phase 2 | Nov 1, 2014 | Celldex Therapeutics |
| NCT01997333 | Phase 2 | Nov 1, 2013 | Celldex Therapeutics |
| NCT01156753 | Phase 2 | Jul 1, 2010 | Celldex Therapeutics |
| NCT00704158 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2008 | CuraGen |
| NCT00412828 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2006 | CuraGen |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Celldex Therapeutics | For profit | 6 | 4 | 3 | 2010 |
| National Cancer Institute (NCI) | Government | 3 | 3 | 1 | 2015 |
| CuraGen | For profit | 2 | 2 | 1 | 2006 |
| Duke University | Academic/Hospital | 1 | 0 | 1 | 2018 |
| PrECOG, LLC. | Academic/Hospital | 1 | 1 | 1 | 2016 |
| University of Texas at Houston | Academic/Hospital | 1 | 0 | 1 | 2015 |
| University of Virginia | Academic/Hospital | 1 | 1 | 1 | 2018 |
7 organizations
Page 1 / 1